A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis

Summary

The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.

Timeline

Start

2022-03-04

Primary completion

2024-07-02

Completion

2025-08-22

Outcome

Met primary endpoint

registry analysis (superiority test); CC-93538 360 mg QW vs Placebo; p = 0.003; Least Square Mean Difference -223.2 (95% CI -370.2 to -76.3); ANCOVA NCT05214768 ↗

Drugs

Indications